RARE DISEASE
Bilirubin encephalopathy
Bilirubin encephalopathy
Bilirubin encephalopathy
Synonyms: Kernicterus
Synonyms: Kernicterus
Synonyms: Kernicterus
Drug discovery
0
drugs
With orphan designations
Overview
Bilirubin encephalopathy is a neurological disorder caused by severe unconjugated hyperbilirubinemia in newborns, leading to bilirubin deposition in brain tissue. Acute bilirubin encephalopathy (ABE) manifests with lethargy, poor feeding, hypertonia, seizures, and abnormal cry, progressing to kernicterus—a chronic condition marked by cerebral palsy, hearing loss, gaze abnormalities, and dental dysplasia. Timely intervention with phototherapy or exchange transfusion is critical to prevent irreversible damage [1][6][9].
Burden
Incidence ranges from 0.9–4.8 cases per 100,000 births in high-income countries, rising to 15% of neonatal deaths in low-resource settings [1][12][14].
Survivors face lifelong disabilities: 30–50% develop athetoid cerebral palsy, hearing loss, or intellectual deficits [3][6][19].
Preventable via TSB monitoring, yet delays in diagnosis/treatment persist globally [2][14][18].
Therapies
Phototherapy: First-line treatment to convert bilirubin into excretable isomers [3][8][16].
Exchange transfusion: Reserved for severe cases (TSB >25 mg/dL or signs of ABE) [3][8][16].
Adjuncts: Intravenous immunoglobulin for isoimmune hemolysis; emerging therapies like phenobarbital (enhances bilirubin conjugation) and metalloporphyrins (inhibit heme oxygenase) [5][8].
Categories: rare inborn errors of metabolism, rare neurological diseases
Research Papers
980 drug discovery papers about Bilirubin encephalopathy, with 2 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
980 drug discovery papers about Bilirubin encephalopathy, with 2 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-07-16 | Efficacy and safety of different doses of intravenous immunoglobulin combined with phototherapy in neonatal hemolytic disease: a systematic review and meta-analysis.
Neonatal hemolytic disease is a major cause of neonatal hyperbilirubinemia and kernicterus. Intravenous immunoglobulin (IVIG) combined with phototherapy is a commonly used clinical intervention; however, the optimal dosing regimen remains controversial. This study aimed to systematically evaluate the efficacy and safety of different doses of IVIG combined with phototherapy in the treatment of neonatal hemolytic disease, and to provide evidence-based guidance for optimizing clinical dosing strategies. A comprehensive literature search was conducted in PubMed, Embase, the Cochrane Library, Web of Science, and Scopus, as well as Chinese databases including CNKI, Wanfang Data, VIP, and the Chinese Biomedical Literature Database, from inception to February 2026. Randomized controlled trials comparing high-dose versus low-dose IVIG combined with phototherapy in neonatal hemolytic disease were included. The primary outcomes included exchange transfusion rate, duration of phototherapy, length of hospital stay, serum bilirubin levels at 24 h, hemoglobin levels at 72 h, and incidence of adverse events. Meta-analysis was performed using RevMan 5.4.1, with fixed- or random-effects models applied according to heterogeneity. A total of 10 randomized controlled trials involving 690 neonates were included. Compared with the low-dose IVIG group, the high-dose IVIG group showed a significantly lower exchange transfusion rate (Peto OR = 0.24, 95% CI: 0.12-0.50, P = 0.0001), corresponding to an approximately 76% reduction in the odds of exchange transfusion. High-dose IVIG was also associated with a shorter duration of phototherapy (MD = - 9.11 h, P = 0.002), a shorter length of hospital stay (MD = - 1.83 days, P = 0.0008), and lower serum bilirubin levels at 24 h (MD = - 38.86, P < 0.00001). No statistically significant differences were observed between the two groups in hemoglobin levels at 72 h or adverse reaction rates (all P > 0.05). Compared with low-dose IVIG, high-dose IVIG combined with phototherapy was associated with lower exchange transfusion rates, shorter phototherapy duration and hospital stay, and lower serum bilirubin levels in neonates with hemolytic disease. No statistically significant differences were observed in hemoglobin levels at 72 h or adverse reaction rates between the two groups. Further large-scale, high-quality randomized controlled trials are warranted to confirm these findings and to clarify the potential impact of blood group subtype on treatment response. •Neonatal hemolytic disease remains a common cause of severe neonatal hyperbilirubinemia. •Intravenous immunoglobulin (IVIG) is frequently used as an adjunctive treatment, but the optimal dosage remains uncertain. • This meta-analysis compared different IVIG dosing regimens using randomized controlled trials only. • High-dose IVIG was associated with lower exchange transfusion rates and improved several short-term clinical outcomes.
2026-06-30 | Efficacy of Bacillus clausii as an adjuvant therapy in pathological neonatal unconjugated hyperbilirubinemia in the Nile Delta region of Egypt: a randomized controlled trial.
Neonatal jaundice (NJ) is a common condition that may progress to serious complications such as kernicterus. Probiotics can also be used for treatment of jaundice by their effect on intestinal motility and microbial flora of the intestine. We aimed to evaluate the effect of probiotic supplementation as an adjuvant therapy in pathological neonatal unconjugated hyperbilirubinemia. A randomized, parallel-group comparative study was conducted on 44 neonates with confirmed pathological unconjugated hyperbilirubinemia admitted to the Neonatal Intensive Care Unit at Tanta University Hospital (Egypt) between May 2024 and April 2025. Participants were randomized (1:1) into two groups: phototherapy alone (control group n = 22) and phototherapy plus oral Bacillus clausii probiotic (probiotic group n = 22). Demographic data and bilirubin fractions were recorded. The primary outcome was the change in bilirubin levels; secondary outcomes included inflammatory biomarkers. Baseline characteristics were comparable between groups. Both groups exhibited significant declines in total serum bilirubin and indirect bilirubin, but only the probiotic group showed a significant reduction in direct bilirubin. By the end of treatment, the probiotic group showed a significantly greater reduction in lipopolysaccharide and tumor necrosis factor-α levels compared with the control group. Hospital stay was significantly shorter with probiotic therapy (3.8 ± 1.18 vs 6.3 ± 2.14 days; P < .001). Bacillus clausii supplementation alongside phototherapy significantly enhanced bilirubin reduction, decreased inflammatory markers, and shortened hospitalization, supporting its role as a beneficial adjunct therapy in neonatal hyperbilirubinemia.
2026-06-08 | Kernicterus and Bilirubin-Induced Neurologic Dysfunction (BIND): Pathophysiology, Clinical Management, and Strategies for Prevention of a Reversible Catastrophe
Kernicterus, or chronic bilirubin encephalopathy, represents a permanent, disabling neurologic condition resulting from the deposition of unconjugated bilirubin in the basal ganglia and brainstem nuclei of neonates. This review provides a comprehensive examination of the condition, beginning with its pathophysiological basis: the passage of lipid-soluble unconjugated bilirubin across an immature or compromised blood-brain barrier, followed by selective neuronal injury mediated by mitochondrial dysfunction, oxidative stress, and apoptosis. The etiological landscape is bifurcated into disorders of increased bilirubin production (hemolysis, polycythemia, birth trauma) and decreased excretion (hypoalbuminemia, UGT1A1 deficiency, breast milk jaundice), with a significant proportion of cases remaining idiopathic. Epidemiology reveals striking disparities by race, sex, and gestational age, with preterm and male infants at highest risk. The clinical progression follows a predictable three-phase acute course—from lethargy and poor feeding to hypertonia and opisthotonos, culminating in hypotonia and apnea—which, if untreated, evolves into chronic choreoathetoid cerebral palsy, auditory neuropathy, and oculomotor deficits. Diagnosis rests on serial bilirubin measurements, hematologic evaluation for hemolysis, and brainstem auditory evoked responses. Management is stratified by severity and includes intensive phototherapy, intravenous immunoglobulins for immune-mediated hemolysis, and exchange transfusion for emergent cases. Prevention remains the cornerstone: universal bilirubin screening, adherence to hour-specific nomograms, early follow-up, and parental education have drastically reduced the incidence in high-resource settings. The prognosis is excellent with early intervention but dismal with delayed recognition. Kernicterus is a largely preventable tragedy, and its continued occurrence—particularly in low- and middle-income countries—represents a failure of systems, not biology.
2026-06-04 | NURSING CARE FOR NEWBORNS WITH HYPERBILIRUBINEMIA AND NEONATAL JAUNDICE PROBLEMS IN THE LAVALETTE HOSPITAL
Introduction: Hyperbilirubinemia is a common clinical problem in newborns, characterised by elevated bilirubin levels which lead to jaundice in neonates. If left untreated, this condition can lead to serious complications such as kernicterus and bilirubin encephalopathy. Methods: This study aims to analyse the nursing care provided to neonates with hyperbilirubinemia and jaundice, using a descriptive case study design at Lavalette Hospital. Participants were two neonates aged six and 17 days, both diagnosed with hyperbilirubinemia. Data were obtained through interviews with parents and nurses, direct observation of nursing actions and analysis of medical records. Data validation was performed using source triangulation. Results: The results of the three-day study showed a decrease in jaundice symptoms after two phototherapy sessions, as indicated by a reduction in the scores for yellow skin, yellow sclera and yellow mucous membranes. Conclusion: Phototherapy was effective in addressing the nursing issue of neonatal jaundice. The success of therapy was also supported by collaboration between medical personnel and family participation. Follow-up care focuses on increasing body weight and providing nutrition to prevent the recurrence of neonatal jaundice.
2026-06-01 | Neonatal Jaundice and the Developing Brain: Pathophysiology, Clinical Management, and Long-Term Neurological Outcome
Neonatal jaundice, characterized by elevated serum bilirubin levels, is a common condition affecting newborns globally. While mild jaundice is often benign, severe hyperbilirubinemia poses a significant risk to neurological development. If left untreated, it can lead to irreversible brain damage, with lifelong implications for affected children. This review aims to examine the impact of neonatal jaundice on pediatric neurological outcomes, focusing on the pathophysiology, risk factors, clinical manifestations, and long-term consequences. A comprehensive analysis of current literature was conducted, including clinical studies and systematic reviews. Emphasis was placed on understanding the neurological sequelae of neonatal jaundice and evaluating the effectiveness of therapeutic interventions. Findings indicate that severe neonatal jaundice is associated with neurological complications such as acute bilirubin encephalopathy and kernicterus. These conditions can result in motor impairments, hearing loss, speech delays, and cognitive dysfunction. Early diagnosis and interventions, such as phototherapy and exchange transfusion, have significantly reduced the incidence of severe outcomes. However, in low-resource settings, delayed diagnosis and inadequate treatment remain substantial challenges, increasing the risk of permanent disability. Neonatal jaundice, if improperly managed, poses serious risks to pediatric neurological health. Timely intervention and improved screening protocols are essential to prevent long-term neurological damage. Further research is needed to explore the subtle neurodevelopmental effects and to enhance care strategies, especially in under-resourced regions. A multidisciplinary approach is crucial to mitigate these risks and improve outcomes for affected children.
2026-07-16 | Efficacy and safety of different doses of intravenous immunoglobulin combined with phototherapy in neonatal hemolytic disease: a systematic review and meta-analysis.
Neonatal hemolytic disease is a major cause of neonatal hyperbilirubinemia and kernicterus. Intravenous immunoglobulin (IVIG) combined with phototherapy is a commonly used clinical intervention; however, the optimal dosing regimen remains controversial. This study aimed to systematically evaluate the efficacy and safety of different doses of IVIG combined with phototherapy in the treatment of neonatal hemolytic disease, and to provide evidence-based guidance for optimizing clinical dosing strategies. A comprehensive literature search was conducted in PubMed, Embase, the Cochrane Library, Web of Science, and Scopus, as well as Chinese databases including CNKI, Wanfang Data, VIP, and the Chinese Biomedical Literature Database, from inception to February 2026. Randomized controlled trials comparing high-dose versus low-dose IVIG combined with phototherapy in neonatal hemolytic disease were included. The primary outcomes included exchange transfusion rate, duration of phototherapy, length of hospital stay, serum bilirubin levels at 24 h, hemoglobin levels at 72 h, and incidence of adverse events. Meta-analysis was performed using RevMan 5.4.1, with fixed- or random-effects models applied according to heterogeneity. A total of 10 randomized controlled trials involving 690 neonates were included. Compared with the low-dose IVIG group, the high-dose IVIG group showed a significantly lower exchange transfusion rate (Peto OR = 0.24, 95% CI: 0.12-0.50, P = 0.0001), corresponding to an approximately 76% reduction in the odds of exchange transfusion. High-dose IVIG was also associated with a shorter duration of phototherapy (MD = - 9.11 h, P = 0.002), a shorter length of hospital stay (MD = - 1.83 days, P = 0.0008), and lower serum bilirubin levels at 24 h (MD = - 38.86, P < 0.00001). No statistically significant differences were observed between the two groups in hemoglobin levels at 72 h or adverse reaction rates (all P > 0.05). Compared with low-dose IVIG, high-dose IVIG combined with phototherapy was associated with lower exchange transfusion rates, shorter phototherapy duration and hospital stay, and lower serum bilirubin levels in neonates with hemolytic disease. No statistically significant differences were observed in hemoglobin levels at 72 h or adverse reaction rates between the two groups. Further large-scale, high-quality randomized controlled trials are warranted to confirm these findings and to clarify the potential impact of blood group subtype on treatment response. •Neonatal hemolytic disease remains a common cause of severe neonatal hyperbilirubinemia. •Intravenous immunoglobulin (IVIG) is frequently used as an adjunctive treatment, but the optimal dosage remains uncertain. • This meta-analysis compared different IVIG dosing regimens using randomized controlled trials only. • High-dose IVIG was associated with lower exchange transfusion rates and improved several short-term clinical outcomes.
2026-06-30 | Efficacy of Bacillus clausii as an adjuvant therapy in pathological neonatal unconjugated hyperbilirubinemia in the Nile Delta region of Egypt: a randomized controlled trial.
Neonatal jaundice (NJ) is a common condition that may progress to serious complications such as kernicterus. Probiotics can also be used for treatment of jaundice by their effect on intestinal motility and microbial flora of the intestine. We aimed to evaluate the effect of probiotic supplementation as an adjuvant therapy in pathological neonatal unconjugated hyperbilirubinemia. A randomized, parallel-group comparative study was conducted on 44 neonates with confirmed pathological unconjugated hyperbilirubinemia admitted to the Neonatal Intensive Care Unit at Tanta University Hospital (Egypt) between May 2024 and April 2025. Participants were randomized (1:1) into two groups: phototherapy alone (control group n = 22) and phototherapy plus oral Bacillus clausii probiotic (probiotic group n = 22). Demographic data and bilirubin fractions were recorded. The primary outcome was the change in bilirubin levels; secondary outcomes included inflammatory biomarkers. Baseline characteristics were comparable between groups. Both groups exhibited significant declines in total serum bilirubin and indirect bilirubin, but only the probiotic group showed a significant reduction in direct bilirubin. By the end of treatment, the probiotic group showed a significantly greater reduction in lipopolysaccharide and tumor necrosis factor-α levels compared with the control group. Hospital stay was significantly shorter with probiotic therapy (3.8 ± 1.18 vs 6.3 ± 2.14 days; P < .001). Bacillus clausii supplementation alongside phototherapy significantly enhanced bilirubin reduction, decreased inflammatory markers, and shortened hospitalization, supporting its role as a beneficial adjunct therapy in neonatal hyperbilirubinemia.
2026-06-08 | Kernicterus and Bilirubin-Induced Neurologic Dysfunction (BIND): Pathophysiology, Clinical Management, and Strategies for Prevention of a Reversible Catastrophe
Kernicterus, or chronic bilirubin encephalopathy, represents a permanent, disabling neurologic condition resulting from the deposition of unconjugated bilirubin in the basal ganglia and brainstem nuclei of neonates. This review provides a comprehensive examination of the condition, beginning with its pathophysiological basis: the passage of lipid-soluble unconjugated bilirubin across an immature or compromised blood-brain barrier, followed by selective neuronal injury mediated by mitochondrial dysfunction, oxidative stress, and apoptosis. The etiological landscape is bifurcated into disorders of increased bilirubin production (hemolysis, polycythemia, birth trauma) and decreased excretion (hypoalbuminemia, UGT1A1 deficiency, breast milk jaundice), with a significant proportion of cases remaining idiopathic. Epidemiology reveals striking disparities by race, sex, and gestational age, with preterm and male infants at highest risk. The clinical progression follows a predictable three-phase acute course—from lethargy and poor feeding to hypertonia and opisthotonos, culminating in hypotonia and apnea—which, if untreated, evolves into chronic choreoathetoid cerebral palsy, auditory neuropathy, and oculomotor deficits. Diagnosis rests on serial bilirubin measurements, hematologic evaluation for hemolysis, and brainstem auditory evoked responses. Management is stratified by severity and includes intensive phototherapy, intravenous immunoglobulins for immune-mediated hemolysis, and exchange transfusion for emergent cases. Prevention remains the cornerstone: universal bilirubin screening, adherence to hour-specific nomograms, early follow-up, and parental education have drastically reduced the incidence in high-resource settings. The prognosis is excellent with early intervention but dismal with delayed recognition. Kernicterus is a largely preventable tragedy, and its continued occurrence—particularly in low- and middle-income countries—represents a failure of systems, not biology.
2026-06-04 | NURSING CARE FOR NEWBORNS WITH HYPERBILIRUBINEMIA AND NEONATAL JAUNDICE PROBLEMS IN THE LAVALETTE HOSPITAL
Introduction: Hyperbilirubinemia is a common clinical problem in newborns, characterised by elevated bilirubin levels which lead to jaundice in neonates. If left untreated, this condition can lead to serious complications such as kernicterus and bilirubin encephalopathy. Methods: This study aims to analyse the nursing care provided to neonates with hyperbilirubinemia and jaundice, using a descriptive case study design at Lavalette Hospital. Participants were two neonates aged six and 17 days, both diagnosed with hyperbilirubinemia. Data were obtained through interviews with parents and nurses, direct observation of nursing actions and analysis of medical records. Data validation was performed using source triangulation. Results: The results of the three-day study showed a decrease in jaundice symptoms after two phototherapy sessions, as indicated by a reduction in the scores for yellow skin, yellow sclera and yellow mucous membranes. Conclusion: Phototherapy was effective in addressing the nursing issue of neonatal jaundice. The success of therapy was also supported by collaboration between medical personnel and family participation. Follow-up care focuses on increasing body weight and providing nutrition to prevent the recurrence of neonatal jaundice.
2026-06-01 | Neonatal Jaundice and the Developing Brain: Pathophysiology, Clinical Management, and Long-Term Neurological Outcome
Neonatal jaundice, characterized by elevated serum bilirubin levels, is a common condition affecting newborns globally. While mild jaundice is often benign, severe hyperbilirubinemia poses a significant risk to neurological development. If left untreated, it can lead to irreversible brain damage, with lifelong implications for affected children. This review aims to examine the impact of neonatal jaundice on pediatric neurological outcomes, focusing on the pathophysiology, risk factors, clinical manifestations, and long-term consequences. A comprehensive analysis of current literature was conducted, including clinical studies and systematic reviews. Emphasis was placed on understanding the neurological sequelae of neonatal jaundice and evaluating the effectiveness of therapeutic interventions. Findings indicate that severe neonatal jaundice is associated with neurological complications such as acute bilirubin encephalopathy and kernicterus. These conditions can result in motor impairments, hearing loss, speech delays, and cognitive dysfunction. Early diagnosis and interventions, such as phototherapy and exchange transfusion, have significantly reduced the incidence of severe outcomes. However, in low-resource settings, delayed diagnosis and inadequate treatment remain substantial challenges, increasing the risk of permanent disability. Neonatal jaundice, if improperly managed, poses serious risks to pediatric neurological health. Timely intervention and improved screening protocols are essential to prevent long-term neurological damage. Further research is needed to explore the subtle neurodevelopmental effects and to enhance care strategies, especially in under-resourced regions. A multidisciplinary approach is crucial to mitigate these risks and improve outcomes for affected children.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.